ロード中...
The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
INTRODUCTION: The treatment of type 2 diabetes mellitus (T2DM) continues to pose challenges for clinicians and patients. The dramatic rise in T2DM prevalence, which has paralleled the rise in obesity, has strained the healthcare system and prompted the search for therapies that not only effectively...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Healthcare
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4065283/ https://ncbi.nlm.nih.gov/pubmed/24729157 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-014-0063-1 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|